Home / Business and Economy / Ennature Bio Pharma Sees Q2 Profit Surge Post-Demerger

Ennature Bio Pharma Sees Q2 Profit Surge Post-Demerger

14 Nov

Summary

Ennature Bio Pharma reported Rs 4.89 crore profit in Q2 FY27.
Quarterly revenue increased to Rs 78.46 crore from Rs 54.14 crore.
This marks the first results after demerger from India Glycols Ltd.

Ennature Bio Pharma announced strong financial performance for the second quarter of Fiscal Year 2027, reporting a profit after tax of Rs 4.89 crore. This achievement represents a significant turnaround from the Rs 1.28 crore loss recorded in the corresponding quarter of the previous fiscal year.

The company's revenue for the September quarter of FY27 surged to Rs 78.46 crore, a considerable increase from Rs 54.14 crore reported a year ago. Furthermore, Ennature Bio Pharma's earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose to Rs 10.34 crore during this period, up from Rs 6.04 crore in the second quarter of FY26.

These results are particularly noteworthy as they are the first quarterly financial disclosures from Ennature Bio Pharma since its demerger from India Glycols Ltd. The company also reported an EBITDA of Rs 10.34 crore, indicating improved operational efficiency and profitability.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.